Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations
30.3.2026 07:45:00 CEST | Business Wire | Press Release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/
Addressing Critical Trade Finance Challenges
The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges.
In many LC transactions, conformity-assessment documents -such as Certificates of Inspection, Certificates of Conformity, or Inspection Reports- are required as part of the documentation package. These documents must be issued prior to export and be verified to ensure LC compliance, which often creates delays and adds operational complexity. The collaboration between Bureau Veritas and Trade Technologies streamlines this process by linking inspection and conformity assessments directly to the trade-finance workflow, enabling faster validation and delivery of the required certificates.
Market Outlook and Growth Potential
The documentary trade sector is forecasted to grow at a 3.1% CAGR through 2029, while receivables finance is projected to expand at 4.2% CAGR during the same period. Documentary trade is expected to remain a core component of the trade finance market well into the 2050s, underscoring the enduring relevance of this collaboration. Current high levels of counterparty and geopolitical uncertainty underscore the value of documentary trade to manage risk in cross-border transactions.
Tangible Benefits for Trade Stakeholders
The collaboration between Trade Technologies and Bureau Veritas promises to deliver meaningful improvements:
- Enhanced Border Efficiency: More streamlined border processes have already contributed to trade cost reductions of up to 5% over the past decade, with ambitious reforms potentially delivering up to 12 percentage points in additional savings.
- Reduced Uncertainty: By combining Trade Technologies' digital trade expertise with Bureau Veritas' deep international trade experience, this collaboration is expected to help exporters, importers, and traders reduce uncertainty and improve visibility.
- Compliance Assurance: The collaboration ensures that applicable standards and/or contractual obligations are met before goods move across borders, strengthening compliance with inspection and conformity requirements.
A Practical Alignment
This strategic collaboration reflects a practical alignment between Trade Technologies, industry-leading digital trade processes and Bureau Veritas’ global network of testing, conformity and inspection experts, enabling better coordination of financial, documentary, and regulatory workflows across global trade corridors.
“Our Certificates of Conformity and Inspection have long served as essential gatekeepers in global supply chains, confirming that goods meet applicable standards before they cross borders”, said Stéphanie Peyrot, Government Services Director for Central Southeast Europe. “Through this collaboration with Trade Technologies, we're now able to integrate these critical documents directly into the trade finance workflow. This means faster processing, greater transparency, and reduced risk for all parties, from exporters and importers to banks and customs authorities. It's about making compliance work for trade, not against it.”
“Bureau Veritas is an important player for vital documents and data to provide certainty of prompt payment under trade finance instruments”, said Kirk Lundburg, CEO of Trade Technologies. “This collaboration simplifies our communication with Bureau Veritas and reduces the time for delivering key data and documents necessary to get our customers paid for their export transactions. We are delighted to partner with Bureau Veritas to reduce risk and complexity for our shared customers.”
***
About Bureau Veritas:
Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers’ excellence and sustainability, the company innovates to help them navigate change.
Created in 1828, Bureau Veritas’ 82,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit http://www.bureauveritas.com, and follow us on LinkedIn.
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.
About Trade Technologies:
Trade Technologies is the leading provider of trade finance automation, connectivity, and transaction management services. Established in 1999, the Company has processed almost USD 195 billion in successful trade transactions for thousands of Exporters. Trade Technologies' innovative solutions, including TradeSharp™ and TradeBridge API, automate and digitize the creation, management, and delivery of documents and data between Corporates, Banks and Buyers. With a global presence in 16 offices across Asia, EMEA and North America, the Company offers a unique blend of technology and expert trade services that optimize transaction processing, enhance cash flow, and provide end-to-end visibility. Clients benefit from faster, more reliable payments and reduced costs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260329411683/en/
Contacts
ANALYST/INVESTOR CONTACTS
Laurent Brunelle
+33 (0)1 55 24 76 09
laurent.brunelle@bureauveritas.com
Colin Verbrugghe
+33 (0)1 55 24 77 80
colin.verbrugghe@bureauveritas.com
Romain Gorge
romain.gorge@bureauveritas.com
Inès Lagoutte
ines.lagoutte@bureauveritas.com
MEDIA CONTACTS
Karine Havas
+33 (0)6 68 63 83 18
karine.havas@bureauveritas.com
Frédéric Vallois
+33 (0)6 21 66 31 04
frederic.vallois@bureauveritas.com
Claudia Strasserra
+39 340 3817265
claudia.strasserra@bureauveritas.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press Release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press Release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press Release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press Release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom